SPCG-2
Orchiectomy plus placebo versus orchiectomy plus cyproteronacetat
Sed posuere consectetur est at lobortis. Donec ullamcorper nulla non metus auctor fringilla. Donec ullamcorper nulla non metus auctor fringilla. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Maecenas faucibus mollis interdum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Maecenas faucibus mollis interdum.
5 publications
Publications of the SPCG-2 trial
Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2
Jørgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen HE
J Urol. 1997
Up-Regulation of the Oligosaccharide Sialyl Lewis-x: A New Prognostic Parameter in Metastatic Prostate Cancer
Jørgensen T, Berner A, Kaalhus O, Tveter KJ Danielsen HE, Bryne M
Cancer Res. 1995
Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer
Jørgensen T, Yogesan K, Skjørten F, Berner A, Tveter KJ, Danielsen HE
Br J Cancer. 1995
Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2
Jørgensen T, Müller C, Kaalhus O, Danielsen HE, Tveter KJ
Eur Urol. 1995
Total androgen suppression: Experience from the Scandinavian Prostate Cancer Group Study No. 2
Jørgensen T, Tveter KJ, Jørgensen LH, SPCG-2 group
Eur Urol. 1993